EFFICACY AND SAFETY OF IBANDRONIC ACID ADMINISTERED INTRAVENOUSLY TO JUVENILE ARTHRITIS PATIENTS WITH SEVERE SYSTEM OSTEOPOROSIS

The article is dedicated to study of efficacy and safety of ibandronic acid administered intravenously to 25 patients suffering from juvenile arthritis and system osteoporosis. It was concluded that administration of 3 mg of ibandronate every 3 months during 76 weeks increase  CTX, which indicates i...

Full description

Saved in:
Bibliographic Details
Published inVoprosy sovremennoĭ pediatrii Vol. 10; no. 6
Main Authors R.V. Denisova, E.I. Alexeeva, V.G. Pinelis, M.I. Bakanov, S.I. Valieva, T.M. Bzarova, K.B. Isaeva, S.Yu. Morev, G.V. Kuznetsova
Format Journal Article
LanguageEnglish
Published "Paediatrician" Publishers LLC 01.01.2011
Subjects
biophosphates
child
ibandronic acid
juvenile arthritis
osteoporosis
treatment
Online AccessGet full text

Cover

More Information
Summary:The article is dedicated to study of efficacy and safety of ibandronic acid administered intravenously to 25 patients suffering from juvenile arthritis and system osteoporosis. It was concluded that administration of 3 mg of ibandronate every 3 months during 76 weeks increase  CTX, which indicates improvement of bone metabolism. During the treatment no subsequent vertebrae fractures have been registered. Increase in bone mass during the ibandronate therapy has been sufficient to allow endoprosthetic hip replacement in 7 patients.Key words: child, juvenile arthritis, osteoporosis, treatment, biophosphates, ibandronic acid. (Voprosy sovremennoi pediatrii —  Current Pediatrics. — 2011; 10 (6): 83–88)
ISSN:1682-5527
1682-5535